# Karuna Therapeutics, Inc.  Share Price Target ‘$324.17’, now -1.7% Downside Potential

- Link: https://www.directorstalkinterviews.com/karuna-therapeutics-inc.share-price-target-324.17-now-1.7-downside-potential/4121148526
- Published: 2024-03-22T12:40:00+00:00
- Author: Charlotte Edwards

**Karuna Therapeutics, Inc.** which can be found using ticker (KRTX) now have 12
analysts in total covering the stock. The consensus rating is pointing to ‘hold’.
The target price High/Low ranges between $330.00 and $260.00 with the average share
target price sitting at $324.17. (at the time of writing). Now with the previous
closing price of $329.83 this now indicates there is a potential downside of -1.7%.
The 50 day MA is $317.67 and the 200 day moving average is $228.83. The company 
has a market capitalization of 12.60B. The stock price for the company is currently
$329.83 USD

 The potential market cap would be $12,383,066,469 based on the market consensus.

The company has a dividend yield of 2.93%. Other points of data to note are a P/
E ratio of -, revenue per share of $0.02 and a -24.71% return on assets.

Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company
creates and delivers transformative medicines for people living with psychiatric
and neurological conditions. Its pipeline is primarily built on the therapeutic 
potential of its product candidate, KarXT (xanomeline-trospium), an oral modulator
of muscarinic receptors that are located both in the central nervous system (CNS),
and various peripheral tissues. KarXT combines xanomeline, a novel muscarinic agonist,
with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic
receptors in the CNS. The Company is developing KarXT for the treatment of acute
psychosis in adults with schizophrenia, as well as for the treatment of psychosis
in Alzheimer’s disease (AD). The Company is also engaged in developing its investigational
TRPC4/5 candidate, KAR-2618, for the treatment of mood and anxiety disorders, and
plan to provide details regarding the expected development of KAR-2618.

Share on: